Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Audio By Carbonatix

MILWAUKEE--(BUSINESS WIRE)--Dec 18, 2024--

Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi .

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, pre-Merger Cara stockholders are expected to own approximately 17.0% of the combined company and pre-Merger Tvardi investors are expected to own approximately 83.0% of the combined company, in each case, prior to certain adjustments. Cara insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Cara by imposing a significant penalty if Cara accepts a competing bid. We are investigating the conduct of Cara’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241218522944/en/

CONTACT: Ademi LLP

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

KEYWORD: WISCONSIN UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL

SOURCE: Ademi LLP

Copyright Business Wire 2024.

PUB: 12/18/2024 07:56 AM/DISC: 12/18/2024 07:56 AM

http://www.businesswire.com/news/home/20241218522944/en